

## NOTICE OF TERMINATION OF LIND SHARE PURCHASE AGREEMENT AND REPAYMENT OF LATEST INSTALMENT TRANCHE

**MELBOURNE (AUSTRALIA) 05 March 2025:** Invion Limited (ASX: IVX) (“**Invion**” or the “**Company**”) has issued a termination notice for the Share Purchase Agreement dated 27 June 2024 (**Agreement**) with Lind Global Fund II, LP (**Lind**), and will be repaying the latest tranche instalment to Lind funded under this Agreement.

The Agreement is a staged private placement in monthly instalments of \$100,000 per month, which may be increased by mutual agreement up to \$500,000 per month, over a 12-month period from June 2024.

There is no cost to Invion for ending this Agreement.

Invion will also repay the latest instalment of \$250,000 provided by Lind that was referenced in the Appendix 2A on 4 March 2025 at a 5% premium. Accordingly, the shares the subject of the Appendix 2A will not be issued.

The Company would like to thank Lind for the support it has provided over the past several months, which was instrumental in helping fund the initiation of the Phase I/II non-melanoma skin cancer trial, as well as other research and development programs.

This announcement was approved for release by Invion's Board of Directors.

---

**Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions:** <https://investors.inviongroup.com/>

### Investor and Media enquiries:

Thian Chew (Chair & CEO)  
T: +61 3 9692 7222  
E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

Brendon Lau (Investor & Media Relations)  
M: +61 409 341 613  
E: [brendon.lau@inviongroup.com](mailto:brendon.lau@inviongroup.com)

### About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

## ASX ANNOUNCEMENT

### About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".

For personal use only